Add-on Acquisition • Life Science

Sobieski & Bradley Acquires Arthrosi Therapeutics

On December 13, 2025, Sobieski & Bradley acquired life science company Arthrosi Therapeutics for 950M USD

Acquisition Context

This is Sobieski & Bradley’s 1st transaction in the Life Science sector.
This is Sobieski & Bradley’s largest (disclosed) transaction.
This is Sobieski & Bradley’s 1st transaction in the United States.
This is Sobieski & Bradley’s 1st transaction in California.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	December 13, 2025
Target	Arthrosi Therapeutics
Sector	Life Science
Buyer(s)	Sobieski & Bradley
Deal Type	Add-on Acquisition
Deal Value	950M USD

Target Company

Arthrosi Therapeutics

San Diego, California, United States

Arthrosi Therapeutics Is focused on developing pozdeutinurad, a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with progressive gout. Arthrosi Therapeutics is based in San Diego, California.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Sobieski & Bradley

South Jordan, Utah, United States

Category	Company
Founded	1987
Sector	Insurance

DESCRIPTION

Sobieski & Bradley, Inc. is a wholesale insurance broker and managing general agent which provides property/casualty, professional liability and other specialty insurance products and services for independent insurance agents and brokers located throughout the West.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: California	1 of 1
Country: United States	1 of 1
Year: 2025	1 of 1
Size (of disclosed)	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - California M&A - United States M&A - 2025 M&A